Needle Free Drug Delivery Device Market - Global Forecast 2026-2032

The Needle Free Drug Delivery Device Market is projected to reach USD 14.76 Billion in 2026. It is expected to continue growing at a CAGR of 13.31%, reaching USD 31.41 Billion by 2032.

The needle-free drug delivery device market is advancing as healthcare systems pursue safer, more patient-centered alternatives to conventional injections. Needle-free injectors, microneedle platforms, transdermal systems, and connected wearable delivery devices are designed to administer biologics, vaccines, insulin, hormones, and pain therapies without a traditional hypodermic needle.

Demand is supported by measurable clinical and operational needs. The World Health Organization has reported that billions of injections are administered globally each year, while the U.S. CDC has estimated hundreds of thousands of sharps injuries annually among hospital-based healthcare personnel. These facts keep needlestick prevention, infection-control efficiency, healthcare worker safety, and medication adherence at the center of procurement decisions.

For manufacturers, providers, and investors, the opportunity is no longer limited to needle aversion. It now includes chronic disease self-management, mass immunization readiness, biologic drug lifecycle management, reduced sharps waste, dose accuracy, and digitally enabled dose tracking across home care and clinical settings.

Transformative Shifts in Needle-Free Delivery

The landscape is shifting from hospital-administered injections toward decentralized care, where patients expect convenient, reliable, and less painful drug delivery at home. Diabetes, autoimmune disorders, migraine, fertility care, hormone therapy, and long-term biologic treatment are increasing the need for repeat-administration systems that combine usability with dose accuracy.

Regulatory expectations are also reshaping product design. Needle-free drug delivery devices must demonstrate biocompatibility, mechanical reliability, human-factors validation, sterility assurance, and, for combination products, performance with the drug formulation itself. This is especially important for biologics and high-viscosity formulations, where delivery force, fill volume, and tissue penetration depth affect clinical performance.

Sustainability and health-worker safety are becoming differentiators. Needle-free systems can reduce reliance on exposed sharps and may lower injury-related workflow burden when properly implemented. Competitive advantage is increasingly tied to evidence generation, device-drug compatibility, connected monitoring, patient training, and scalable manufacturing quality.

Cumulative Impact of AI on Needle-Free Devices

Artificial intelligence is beginning to influence the needle-free drug delivery device value chain through design optimization, manufacturing quality, connected adherence support, and post-market surveillance. AI-enabled simulation can help engineers evaluate nozzle geometry, injection pressure, microneedle array performance, wearable device mechanics, and skin-interaction variables before physical prototyping.

In production, machine vision and predictive analytics can strengthen defect detection for micro-scale components, springs, cartridges, seals, reservoirs, and wearable device assemblies. These applications are particularly relevant where small dimensional variations can affect dose delivery, leakage risk, or patient comfort.

In patient use, AI can support dose reminders, adherence risk scoring, injection-site rotation guidance, and anomaly detection from connected devices. However, AI adoption must be governed by cybersecurity, explainability, data privacy, clinical validation, and regulatory controls, particularly when software influences clinical decision-making or dosing behavior.

Key Regional Insights for Needle-Free Drug Delivery

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia combine large chronic disease populations with growing vaccine infrastructure, manufacturing capability, and digital health adoption. China and India offer scale for diabetes care, immunization programs, and cost-sensitive device deployment, while Japan, South Korea, and Australia emphasize high-quality devices, aging-population care, home-based treatment, and regulated innovation pathways.

North America remains a leading commercialization region due to advanced reimbursement systems, high biologics use, diabetes prevalence, strong regulated pathways for device-drug combination products, and established home healthcare adoption. The United States is especially important for connected needle-free injectors, wearable injectors, autoinjector alternatives, and pediatric or needle-phobia applications, while Canada supports adoption through quality-focused public healthcare systems and patient safety priorities.

Europe benefits from mature medical device oversight, strong pharmacovigilance systems, and demand for safer occupational healthcare practices, with the EU MDR reinforcing clinical evidence, post-market surveillance, and risk management requirements. Latin America shows opportunity in Brazil and Mexico as access to chronic disease treatment and private healthcare expands. The Middle East is supported by high diabetes burden, health modernization, and premium hospital infrastructure, while Africa presents targeted opportunities in vaccination initiatives, infectious disease programs, and diabetes care, with adoption influenced by affordability, training, procurement models, and supply-chain resilience.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as public health programs, expanding middle-class healthcare access, and regional manufacturing initiatives support adoption of user-friendly drug delivery technologies. Demand is linked to vaccination delivery, diabetes management, and primary care access, while market entry requires pricing discipline, distributor quality, multilingual patient education, and clinician training.

The GCC is positioned for premium adoption through advanced hospital systems, high diabetes burden, and government investment in health modernization. The European Union offers a structured but demanding environment where MDR compliance, clinical evidence, post-market surveillance, usability engineering, and sustainability considerations are central to product acceptance.

BRICS countries represent major volume potential, led by China, India, and Brazil, but success depends on localization, affordability, domestic regulatory navigation, and partnerships that support training and service availability. G7 markets remain the benchmark for evidence-based commercialization, connected device integration, cybersecurity expectations, and combination product approvals. NATO countries, while not a healthcare trade bloc, include many high-income systems focused on medical preparedness, resilient supply chains, occupational safety, and sharps-safety standards.

Key Country Insights for Needle-Free Drug Delivery

The United States leads in innovation, clinical research activity, regulated device pathways, and use of biologics for chronic and specialty diseases. Canada emphasizes safety, quality, and access through provincial healthcare systems, while Mexico offers manufacturing proximity, medical device production capability, and growing chronic care demand. Brazil is the most influential Latin American market, supported by a large population, public immunization experience, and expanding private healthcare use.

In Europe, the United Kingdom, Germany, France, Italy, and Spain present strong demand for evidence-backed needle-free systems in home care, vaccination, and specialty drug delivery. Germany and France are particularly important for reimbursement scrutiny, clinical validation, and quality requirements, while the United Kingdom supports digital health integration and real-world evidence. Italy and Spain offer adoption potential through aging populations and chronic disease management needs. Russia remains relevant through domestic healthcare demand, although sanctions, procurement constraints, and regulatory complexity can affect market access.

China and India are central to long-term scale because of population size, diabetes prevalence, vaccine capacity, and manufacturing ecosystems. Japan prioritizes quality, aging-population care, and patient-friendly delivery systems suited to home treatment. South Korea combines digital health capability with advanced device manufacturing, while Australia offers a transparent regulatory environment, strong safety standards, and adoption potential for reliable home-based therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize drug-device compatibility early, especially for biologics, peptides, vaccines, insulin, hormones, and high-viscosity formulations. Evidence should include dose accuracy, bioavailability, user preference, injection-site tolerability, leakage performance, and performance across skin types, age groups, and care settings.

Companies should invest in human-factors engineering, connected adherence features, cybersecurity, and manufacturability from the start. Partnerships with pharmaceutical firms, contract manufacturers, diabetes care providers, vaccination programs, payers, and digital health platforms can accelerate commercialization and strengthen real-world evidence generation.

Market access strategies should be region-specific. Premium markets require strong clinical, usability, safety, and health-economic evidence, while emerging markets need cost-effective designs, training materials, local service models, and durable supply chains. Privacy, software validation, and post-market surveillance must be built into connected needle-free delivery platforms.

Research Methodology

This executive summary is based on a structured secondary-research approach using publicly available, verifiable sources, including global health agencies, regulatory guidance, clinical literature, standards bodies, healthcare safety references, and public health data. The analysis emphasizes validated industry drivers such as chronic disease management, vaccination delivery, sharps injury prevention, home healthcare, biologic therapy administration, and device-drug combination requirements.

The methodology triangulates qualitative and quantitative indicators across regions, country healthcare infrastructure, regulatory maturity, disease burden, technology readiness, manufacturing capability, and commercialization feasibility. No unsupported proprietary market-size, market-share, or forecasting claims are used; insights are framed around documented healthcare needs, regulatory realities, and observable technology trends.

Findings are reviewed for consistency with medical device dynamics, including human-factors validation, manufacturing quality, sterility assurance, risk management, cybersecurity, post-market surveillance, and evidence requirements for clinical adoption.

Conclusion

Needle-free drug delivery devices are moving from niche alternatives to strategic platforms for safer, more convenient, and more scalable therapy administration. The strongest opportunities are emerging where chronic disease prevalence, biologic therapy growth, vaccine readiness, healthcare worker safety, and home-based care converge.

AI, connected health, and advanced materials will improve device design, quality control, adherence support, and real-world monitoring, but regulatory rigor and clinical evidence will determine adoption. Organizations that combine patient-centered engineering with robust drug-device validation and region-specific market access strategies will be best positioned to lead.

The market outlook is defined by practical healthcare value: reducing needle-related barriers, supporting safer care delivery, improving treatment adherence, and enabling reliable drug administration outside traditional clinical settings.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Needle Free Drug Delivery Device Market, by Product Type

7.1. Introduction
7.2. Jet Injector
7.2.1. Gas Powered
7.2.2. Spring Based
7.3. Microarray Patch
7.3.1. Dissolvable Microarray
7.3.2. Hollow Microarray
7.3.3. Solid Microarray

8. Needle Free Drug Delivery Device Market, by Drug Type

8.1. Introduction
8.2. Insulin
8.2.1. Basal Insulin
8.2.1.1. Intermediate Acting Insulin
8.2.1.2. Long Acting Insulin
8.2.2. Bolus Insulin
8.2.2.1. Rapid Acting Insulin
8.2.2.2. Short Acting Insulin
8.3. Vaccines
8.3.1. COVID-19 Vaccine
8.3.1.1. Mrna Vaccine
8.3.1.2. Viral Vector Vaccine
8.3.2. Influenza Vaccine
8.3.2.1. H5N1 Influenza
8.3.2.2. Seasonal Influenza

9. Needle Free Drug Delivery Device Market, by Administration Route

9.1. Introduction
9.2. Intradermal
9.3. Intramuscular
9.4. Subcutaneous

10. Needle Free Drug Delivery Device Market, by Application

10.1. Introduction
10.2. Dermatology
10.3. Diabetes Management
10.4. Immunization
10.5. Pain Management

11. Needle Free Drug Delivery Device Market, by End User

11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Home Care Settings
11.5. Hospitals

12. Needle Free Drug Delivery Device Market, by Distribution Channel

12.1. Introduction
12.2. Offline
12.3. Online

13. Needle Free Drug Delivery Device Market, by Region

13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East

14. Needle Free Drug Delivery Device Market, by Group

14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC

15. Needle Free Drug Delivery Device Market, by Country

15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. 3M Company
17.2. Antares Pharma, Inc.
17.3. Becton, Dickinson and Company (BD)
17.4. Bioject Medical Technologies Inc.
17.5. Crossject SA
17.6. Endo International plc
17.7. Gerresheimer AG
17.8. Haselmeier GmbH
17.9. Injex Pharma AG
17.10. Inovio Pharmaceuticals, Inc.
17.11. Medical International Technology, Inc.
17.12. National Medical Products Inc.
17.13. Nemera Development S.A.
17.14. NuGen Medical Devices Inc.
17.15. PenJet Corporation
17.16. PharmaJet, Inc.
17.17. Portal Instruments, Inc.
17.18. Schott AG
17.19. SHL Medical AG
17.20. Stevanato Group S.p.A.
17.21. Valeritas Holdings, Inc.
17.22. West Pharmaceutical Services, Inc.
17.23. Ypsomed Holding AG
17.24. Zogenix, Inc.

List of Figures

FIGURE 1. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL JET INJECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL JET INJECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL JET INJECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GAS POWERED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GAS POWERED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GAS POWERED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SPRING BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SPRING BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SPRING BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MICROARRAY PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MICROARRAY PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MICROARRAY PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DISSOLVABLE MICROARRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DISSOLVABLE MICROARRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DISSOLVABLE MICROARRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL HOLLOW MICROARRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HOLLOW MICROARRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HOLLOW MICROARRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SOLID MICROARRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SOLID MICROARRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SOLID MICROARRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BASAL INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BASAL INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BASAL INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTERMEDIATE ACTING INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTERMEDIATE ACTING INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTERMEDIATE ACTING INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LONG ACTING INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LONG ACTING INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LONG ACTING INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BOLUS INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BOLUS INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BOLUS INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL RAPID ACTING INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RAPID ACTING INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL RAPID ACTING INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SHORT ACTING INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SHORT ACTING INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SHORT ACTING INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COVID-19 VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL COVID-19 VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL COVID-19 VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MRNA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MRNA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MRNA VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL H5N1 INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL H5N1 INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL H5N1 INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SEASONAL INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SEASONAL INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SEASONAL INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 129. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 130. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 131. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 132. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 133. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 134. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 135. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 136. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 137. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 138. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 140. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 174. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 175. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 176. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 177. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 178. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 179. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 180. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 181. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 182. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 183. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 184. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 185. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 205. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 206. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 207. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 208. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 209. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 210. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 211. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 212. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 213. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 214. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 215. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 220. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 221. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 222. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 223. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 224. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 225. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 226. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 227. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 228. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 229. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 230. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 231. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 235. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 236. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 237. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 238. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 239. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 240. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 241. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 242. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 243. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 244. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 245. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 246. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 265. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 266. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 267. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 268. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 269. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 270. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 271. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 272. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 273. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 274. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 275. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 276. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 279. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 280. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 281. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 282. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 283. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 284. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 285. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 286. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 287. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 288. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 289. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 290. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 291. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 294. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 296. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 297. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 298. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 299. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 300. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 301. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 302. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 303. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 304. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 305. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 306. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 307. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. CHINA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 314. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 324. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 326. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2017-2032 (USD MILLION)
TABLE 327. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2017-2032 (USD MILLION)
TABLE 328. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 329. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2017-2032 (USD MILLION)
TABLE 330. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2017-2032 (USD MILLION)
TABLE 331. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2017-2032 (USD MILLION)
TABLE 332. JAPAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES,

Companies Mentioned

3M Company
Antares Pharma, Inc.
Becton, Dickinson and Company (BD)
Bioject Medical Technologies Inc.
Crossject SA
Endo International plc
Gerresheimer AG
Haselmeier GmbH
Injex Pharma AG
Inovio Pharmaceuticals, Inc.
Medical International Technology, Inc.
National Medical Products Inc.
Nemera Development S.A.
NuGen Medical Devices Inc.
PenJet Corporation
PharmaJet, Inc.
Portal Instruments, Inc.
Schott AG
SHL Medical AG
Stevanato Group S.p.A.
Valeritas Holdings, Inc.
West Pharmaceutical Services, Inc.
Ypsomed Holding AG
Zogenix, Inc.

Table Information

Report Attribute	Details
No. of Pages	181
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 14.76 Billion
Forecasted Market Value ( USD ) by 2032	$ 31.41 Billion
Compound Annual Growth Rate	13.3%
Regions Covered	Global
No. of Companies Mentioned	24

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in Needle-Free Delivery

Cumulative Impact of AI on Needle-Free Devices

Key Regional Insights for Needle-Free Drug Delivery

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Key Country Insights for Needle-Free Drug Delivery

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

COVID-19 Drug Delivery Devices - Global Strategic Business Report

Drug Delivery Devices Market - Global Forecast 2026-2032

Needle-Free Drug Delivery Devices Market

Needle-Free Drug Delivery Devices Market Report 2026

Subcutaneous Biologics Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biologic, Type of Therapy, End User, Payment Method Employed, Therapeutic Area, Drug Delivery Device, Geographical Regions, Leading Players and Sales Forecast of Drugs